The development of the metabolic syndrome and insulin resistance after adjuvant treatment for breast cancer

Cancer Nursing

Volumn 37, Issue 5, 2014, Pages 355-362

  Guinan, Emer M ^a   Connolly, Elizabeth M ^b   Healy, Laura A ^b   Carroll, Paul A ^b   Kennedy, M John ^b   Hussey, Juliette ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

Breast cancer; Insulin resistance; Metabolic syndrome; Prognosis

Indexed keywords

ANTHRACYCLINE; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ANTHROPOMETRY; ARTICLE; BLOOD SAMPLING; BODY FAT; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; DIET RESTRICTION; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIFESTYLE; MAJOR CLINICAL STUDY; MASTECTOMY; MCNEMAR TEST; METABOLIC PARAMETERS; METABOLIC SYNDROME X; OBESITY; OUTCOME ASSESSMENT; PREMENOPAUSE; PRIORITY JOURNAL; SCREENING; SMOKING; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WIDE EXCISION; ADULT; AGED; BREAST NEOPLASMS; COMPLICATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SURVIVOR;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MIDDLE AGED; SURVIVORS;

EID: 84906933579     PISSN: 0162220X     EISSN: 15389804     Source Type: Journal    
DOI: 10.1097/NCC.0b013e3182a40e6d     Document Type: Article

References (43)

1. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: AICR; 2007
2. Lynch BM, Neilson HK, Friedenreich CM. Physical activity and breast cancer prevention. Recent Results Cancer Res. 2011;186:13-42
3. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917
4. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: Systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123(3):627-635
5. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA. 2005;293(20): 2479-2486
6. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer. 2006;119(1):236-238
7. Goodwin PJ, Ennis M, Pritchard KI, et al. Insulin- and obesity-related variables in early-stage breast cancer: Correlations and time course of prognostic associations. J Clin Oncol. 2012;30(2):164-171
8. Duggan C, Irwin ML, Xiao L, et al. Associations of insulin resistance and adiponectin withmortality in women with breast cancer.J Clin Oncol. 2011; 29(1):32-39
9. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27(21):3437-3444
10. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001;344(26):1997-2008
11. Hormes JM, Lytle LA, Gross CR, Ahmed RL, Troxel AB, Schmitz KH. The body image and relationships scale: Development and validation of a measure of body image in female breast cancer survivors. J Clin Oncol. 2008;26(8):1269-1274
12. Berger AM, Gerber LH, Mayer DK. Cancer-related fatigue: Implications for breast cancer survivors. Cancer. 2012;118(8 suppl):2261-2269
13. Demark-Wahnefried W, Rimer BK, Winer EP. Weight gain in women diagnosed with breast cancer. J Am Diet Assoc. 1997;97(5):519-526
14. Campbell KL, Lane K, Martin AD, Gelmon KA, McKenzie DC. Resting energy expenditure and body mass changes in women during adjuvant chemotherapy for breast cancer. Cancer Nursing. 2007;30(2):95-100
15. Del Rio G, Zironi S, Valeriani L, et al. Weight gain in women with breast cancer treated with adjuvant cyclophosphomide, methotrexate and 5-fluorouracil: Analysis of resting energy expenditure and body composition. Breast Cancer Res Treat. 2002;73(3):267-273
16. Demark-WahnefriedW, Peterson BL, Winer EP, et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2001;19(9):2381-2389
17. Irwin ML, Crumley D, McTiernan A, et al. Physical activity levels before and after a diagnosis of breast carcinoma: The Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer. 2003;97(7):1746-1757
18. Courneya KS, Katzmarzyk PT, Bacon E. Physical activity and obesity in Canadian cancer survivors: Population-based estimates from the 2005 Canadian Community Health Survey. Cancer. 2008;112(11):2475-2482
19. Caan BJ, KwanML, Shu XO, et al. Weight change and survival after breast cancer in the after breast cancer pooling project. Cancer Epidemiol Biomarkers Prev. 2012;21(8):1260-1271
20. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881-887
21. Dominguez LJ, Barbagallo M. The cardiometabolic syndrome and sarcopenic obesity in older persons.J Cardiometab Syndr. 2007;2(3):183-189
22. Aubertin-Leheudre M, Lord C, Goulet ED, Khalil A, Dionne IJ. Effect of sarcopenia on cardiovascular disease risk factors in obese postmenopausal women. Obesity (Silver Spring). 2006;14(12):2277-2283
23. Kaaja RJ. Metabolic syndrome and the menopause. Menopause Int. 2008; 14(1):21-25
24. World Health Organization. Waist circumference and waist-hip ratio. Report of aWHOExpert Consultation.December 8-11, 2008; Geneva, Switzerland,
25. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med. 1998;15(7):539-553
26. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289(19):2560-2572
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations inman. Diabetologia. 1985;28(7):412-419
28. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645
29. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(suppl 1):S64YS71
30. Hanas R, John G. 2010 consensus statement on the worldwide standardization of the hemoglobin A1c measurement. Diabetes Med. 2010; 27(7):737-738
31. Hickish T, Astras G, Thomas P, et al. Glucose intolerance during adjuvant chemotherapy for breast cancer. J Natl Cancer Inst. 2009;101(7):537
32. Nichols HB, Trentham-Dietz A, Egan KM, et al. Body mass index before and after breast cancer diagnosis: Associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1403-1409
33. Chapman JAW, Meng D, Shepherd L, et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst. 2008;100(4):252-260
34. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study. Breast Cancer Res. 2011;13(3):R64.
35. Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, et al. Management of cardiovascular risk in the perimenopausal women: A consensus statement of European cardiologists and gynecologists. Climacteric. 2007;10(6):508-526
36. Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity?. Curr Opin Endocrinol Diabetes Obes. 2012;19(2):81-87
37. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316(2):129-139
38. Pichard C, Plu-Bureau G, Neves ECM, Gompel A. Insulin resistance, obesity and breast cancer risk. Maturitas. 2008;60(1):19-30
39. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88(6):2404-2411
40. Poehlman ET, TothMJ, Gardner AW. Changes in energy balance and body composition at menopause: A controlled longitudinal study. Ann Intern Med. 1995;123(9):673-675
41. Pani LN, Korenda L, Meigs JB, et al. Effect of aging on A1C levels in individuals without diabetes: Evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care. 2008;31(10):1991-1996
42. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163(4):427-436
43. Thomson CA, Thompson PA, Wright-Bea J, Nardi E, Frey GR, Stopeck A. Metabolic syndrome and elevated C-reactive protein in breast cancer survivors on adjuvant hormone therapy. J Womens Health (Larchmt). 2009; 18(12):2041-2047.